Evidence map›Paper›PMID 39699276›Full record

ArticleCancer biology & therapy2025

Daurisoline inhibits glycolysis of lung cancer by targeting the AKT-HK2 axis.

Shi-Ming Tan, Lan Luo, Yi-Fu He, Wei Li, Xin-Xing Wan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. mFrontiers in cell and developmental biology · 2026
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shi-Ming TanDepartment of Hematology, The Third Xiangya Hospital, Central South University, Changsha, China.
Lan LuoDepartment of Obstetrics and Gynecology, The Third Xiangya Hospital, Central South University, Changsha, China.
Yi-Fu HeDepartment of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, China.
Wei LiDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, China.
Xin-Xing WanDepartment of Endocrinology, The Third Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-6617-0331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer, one of the most prevalent tumors, remains a clinical challenge with a poor five-year survival rate. Daurisoline, a bis-benzylisoquinoline alkaloid derived from the traditional Chinese herb Menispermum dauricum, is known to suppress tumor growth effectively. However, its precise mechanism of action remains unclear. In this study, we demonstrate that Daurisoline targets glycolysis and reduces the protein level of HK2, thereby inhibiting lung cancer progression. Mechanistic investigations reveal that Daurisoline directly binds to AKT and antagonizes the AKT-GSK3β-c-Myc-HK2 signaling axis. Furthermore, in an animal model, we validate the in vivo anti-tumor effect of Daurisoline without any observable side effects. Overall, our findings suggest that Daurisoline holds potential as an anti-tumor agent through its targeting of glycolysis.

Indexed as

GlycolysisHexokinaseLung NeoplasmsProto-Oncogene Proteins c-aktAnimalsBenzylisoquinolinesCell Line, TumorCell ProliferationHumansMiceMice, NudeSignal TransductionXenograft Model Antitumor AssaysBenzylisoquinolinesHexokinaseHK2 protein, humanProto-Oncogene Proteins c-aktAKTdaurisolineHK2Lung cancer

Identifiers

PMID39699276
PMCPMC11660295

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.